Prevention of major venous thromboembolism following total hip or knee replacement: A randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial)

International Angiology

Volumn 25, Issue 4, 2006, Pages 335-342

  Haas, Sylvia ^a   Breyer, H G ^b   Bacher, H P ^c   Fareed, J ^d   Misselwitz, F ^e   Victor, N ^f   Weber, J ^g   Volkers, P ^h   Ritter, P ^h   Neiss, A ^h   Reid, Ulrike ^h   Hochreiter, J ^h   Ditmar, R ^h   Fria V ^h   Janecek, M ^h   Koudela, K ^h   Kubes J ^h   Pesek J ^h   Sigut Z ^h   Stedry V ^h   Vrzala, J ^h   Boese Landgraf, J ^h   Burghart, H ^h   Faensen, M ^h   Fritsche, H M ^h   Gummel, J ^h   Griss, P ^h   Haas, N ^h   Hertel, E ^h   Kleinfeld, F ^h   Leonhard, T ^h   Matzen, K ^h   Merk, H ^h   Mouret, P ^h   Noack, W ^h   Oestern, H J ^h   Primbs, P ^h   Reichelt, A ^h   Rudolph, H ^h   Schmelz, H ^h   Schulitz, K P ^h   Schulze, K J ^h   Schunck, R ^h   Speck, M ^h   Streifinger, W ^h   Thielemann, F ^h   Tischer, K ^h   Voelcker, H ^h   Wilker, D ^h   Zippel, H ^h   Kl'oc, J ^h   Maresch, P ^h   Vasko G ^h   Vitkovsy J ^h   Crawfurd, E ^h   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Sankt Gertrauden Krankenhaus   (Germany)

^c ABBOTT LABORATORIES   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e ABBOTT GMBH AND CO KG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Department of Vascular Surgery   (Germany)

^h NONE

Author keywords

Arthroplasty, replacement, hip; Arthroplasty, replacement, knee; Heparin, low molecular weight; Reviparin; Thromboembolism, prevention and control

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; REVIPARIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTIVE SURGERY; FATALITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHLEBOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SIDE EFFECT; SURGICAL MORTALITY; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; WOUND HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33847684665     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr et al. Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S-175S.
2. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R et al. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37.
3. Davidson BL. What are the most reliable detection methods for deep vein thrombosis and pulmonary embolism to be used as endpoints in trials of venous thromboprophylaxis? Haemostasis 1998;28:113-9.
4. Prentice CR. Are symptomatic endpoints acceptable in venous thromboprophylactic studies? Haemostasis 1998;28 Suppl 3:109-12.
5. Girard P, Musset D, Parent F, Maitre S, Phlippoteau C, Simonneau G. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999;116:903-8.
6. Meignan M, Rosso J, Gauthier H, Brunengo F, Claudel S, Sagnard L et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000;160:159-64.
7. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider on Clinical Investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. London: 2000.
8. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 Suppl):64S-94S.
9. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications: a review. Arch Pathol Lab Med 2000;124:1657-66.
10. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-10.
11. German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. Arch Orthop Trauma Surg 1992;111:110-20.
12. Eriksson BI, Kalebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991;73:484-93.
13. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-9.
14. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
15. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998;9:499-505.
16. Planes A. Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 1993;4 Suppl 1:S33-S35.
17. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-41.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
19. Ahmad S, Untch B, Haas S, Hoppenstaedt DA, Misselwitz F, Messmore HL et al. Differential prevalence of anti-heparin platelet factor 4 immunoglobulin subtypes in patients treated with clivarin and heparin. Implications in the HIT pathogenesis. Mol Cell Biochem 2004;258:163-70.
20. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
21. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998;158:873-8.
22. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995;74:1428-31.
23. Planes A, Vochelle N, Ferru J, Przyrowski D, Clerc J, Fagola M et al. Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 1986;16:152-8.
24. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 1988;75:1053-7.
25. Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988;75:888-91. Erratum in: Br J Surg 1988;75:1077.
26. Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991;151:1621-4.
27. Fauno P, Suomalainen O, Rehnberg V, Hansen TB, Kroner K, Soimakallio S et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am 1994;76:1814-8.
28. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-5.
29. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Relevance of systematic venographic outcomes in venous thromboembolism (VTE) prophylaxis studies: lessons from the pentasaccharide (Fondaparinux, Arixtra®) clinical program. Blood 2001;98:1144.
30. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15.
31. Turpie AGG, Bauer KA, Erikson BI, Lassen MR for the PENTATHLON 2000 Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomized double-blind trial. Lancet 2002;359:1721-6.
32. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
33. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the EPHESUS Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip surgery: a randomized double-blind comparison. Lancet 2002;359:1715-20.
34. Eriksson BI, Bauer KA, Lassen, MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
35. Ahmad S, Haas S, Hoppensteadt D, Lietz H, Reid U, Bender N et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin platelet factor 4 antibodies. Thromb Res 2003;108:49-55.